<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05061992</url>
  </required_header>
  <id_info>
    <org_study_id>HUM00204056</org_study_id>
    <nct_id>NCT05061992</nct_id>
  </id_info>
  <brief_title>A Trial to Improve Quality of Life in People With Cirrhosis</brief_title>
  <official_title>A Trial to Improve Quality of Life in People With Cirrhosis - the Michigan Kristalose Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is being completed to evaluate whether a crystallized form of lactulose&#xD;
      (Kristalose) will improve quality of life, sleep and cognitive function in patients with&#xD;
      cirrhosis that have not been diagnosed with Hepatic Encephalopathy (HE), but report reduced&#xD;
      quality of life.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 10, 2021</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Short Form-8 Health Survey (SF-8) at 28 days</measure>
    <time_frame>28 days</time_frame>
    <description>The SF-8 is an abbreviated version of an original 36-item health survey (SF-36). It is a generic multipurpose quality of life instrument. It contains psychometrically based physical and mental health summary measures. The eight domains include general health, physical functioning, role physical, bodily pain, vitality, social functioning, mental health and role emotional (0 no quality of life-100 highest quality of living).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Lactulose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>No treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects will complete baseline and outcome assessments at 28 days and no intervention or placebo will be prescribed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lactulose</intervention_name>
    <description>Participants will take 20 grams (dissolved in 4ounces of water/beverage) doses of lactulose twice daily (upon awakening and then 4 hours later) for 28 days.&#xD;
In addition, outcome measurements will be completed at baseline and day 28.</description>
    <arm_group_label>Lactulose</arm_group_label>
    <other_name>Kristalose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of cirrhosis - must meet one of the following criteria:&#xD;
&#xD;
               1. liver biopsy, OR&#xD;
&#xD;
               2. history of cirrhosis complication: ascites, variceal bleeding, hepatic&#xD;
                  encephalopathy, OR&#xD;
&#xD;
               3. 2 of the following 4 criteria:&#xD;
&#xD;
                    1. Ultrasound, Computed tomography (CT) or Magnetic resonance imaging (MRI)&#xD;
                       findings of cirrhosis (cirrhotic appearing liver, splenomegaly, varices,&#xD;
                       ascites)&#xD;
&#xD;
                    2. Fibroscan liver stiffness score &gt;13 Kilopascal (kPa)&#xD;
&#xD;
                    3. Laboratory testing: aspartate aminotransferase (AST)/platelet ratio index&#xD;
                       (APRI) &gt;2.0&#xD;
&#xD;
                    4. CT, MRI or Esophagogastroduodenoscopy (EGD) showing presence of esophageal&#xD;
                       varices&#xD;
&#xD;
                       Exclusion Criteria:&#xD;
&#xD;
          -  Non-English speaking&#xD;
&#xD;
          -  Pregnancy (self-reported)&#xD;
&#xD;
          -  Unable or unwilling to provide consent&#xD;
&#xD;
          -  History of liver transplant&#xD;
&#xD;
          -  Disorientation at the time of enrollment, Dementia, or Treated Memory Disorder&#xD;
&#xD;
          -  History of prior lactulose use or HE within 6 months&#xD;
&#xD;
          -  Metastatic solid malignancy or blood malignancy&#xD;
&#xD;
          -  Hemoglobin A1C &gt; 12 (within past year)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elliot Tapper, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Samantha Nikirk</last_name>
    <phone>734-232-4182</phone>
    <email>samjwalk@med.umich.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samantha Nikirk</last_name>
      <phone>734-232-4182</phone>
      <email>samjwalk@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Elliot Tapper, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 20, 2021</study_first_submitted>
  <study_first_submitted_qc>September 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 30, 2021</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Elliot B. Tapper</investigator_full_name>
    <investigator_title>Assistant Professor of Internal Medicine</investigator_title>
  </responsible_party>
  <keyword>Hepatic Encephalopathy</keyword>
  <keyword>Liver Disease</keyword>
  <keyword>Cirrhosis and portal hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lactulose</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

